Lung cancer trials in Netherlands

In Netherlands 142 Also abroad 2744

142 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Groningen, Nijmegen, Rotterdam
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Groningen
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Amersfoort, Nijmegen, 'S-Hertogenbosch, Tilburg
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Amsterdam, Heerlen, Leeuwarden, Maastricht, Utrecht
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
Phase 1Taking people
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
Where
Amsterdam
Age
18 years and over
People
20
Run by
The Netherlands Cancer Institute
See details and how to joinNCT07436858 · EU 2026-525568-17-00
Phase 3Taking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Amersfoort, Breda, Groningen, Harderwijk, Hilversum, Zwolle
Age
18 years and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00
Phase 1/2Taking people
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Where
Amsterdam, Leiden, Utrecht
Age
18 years and over
People
616 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00
No phaseTaking people
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
Where
Groningen
Age
18 years and over
People
600 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Breda, Hilversum
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 1/2Not yet taking people in Netherlands
PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER
Where
Nijmegen
Age
18 years and over
People
40 worldwide
Run by
Radboud universitair medisch centrum Stichting
See details and how to join2025-524791-30-00
Phase 1Taking people
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Where
Amsterdam
Age
18 years and over
People
12
Run by
Boehringer Ingelheim
See details and how to joinNCT05963867
Phase 3Taking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Heerlen, 'S-Hertogenbosch, Tilburg
Age
18 years and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
Phase 2/3Not yet taking people in Netherlands
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Where
Amsterdam, Harderwijk
Age
18 years and over
People
173 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Amsterdam
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Harderwijk, Leiden, Nijmegen
Age
18 years and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
Phase 1Taking people
Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
Where
Amsterdam, Groningen, Leiden, Utrecht
Age
18 years and over
People
330 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509571-16-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Amersfoort, Amsterdam, Arnhem, Breda, Harderwijk, Leidschendam, Zwolle
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Amsterdam, Leiden, Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 2Not yet taking people in Netherlands
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
Where
Amsterdam, Leiden
Age
18 years and over
People
30
Run by
The Netherlands Cancer Institute
See details and how to joinNCT07808138 · EU 2025-524305-32-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Amsterdam, Nijmegen, Utrecht
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Amsterdam, Groningen
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Amsterdam, Leiden
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 1Taking people
A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
Where
Amsterdam, Groningen, Leiden, Utrecht
Age
18 years and over
People
180 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509572-42-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Amsterdam
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Arnhem, Maastricht
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00